0 1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Æ Ø Å
Ønsker du salgsvekst?
B2B Connect er en plattform hvor bedrifter som trenger salgsmøter kan benytte seg av så mange profesjonelle møtebookere de ønsker, fra en stor pool.
Du betaler kun per booket (og gjennomført) salgsmøte, og pris per salgsmøte bestemmer du selv. Det er ingen bindinger, og ingen oppstarts- eller abonnementsavgift. Prøve oss med kun 3 møter?
Navn | Norinnova AS |
---|---|
Orgnr/født år | 957915035 |
Ant aksjer | 16,711 |
Omsetning | 34,034 |
Driftsresultat | -1,650 |
Egenkapital | 71,007 |
Ant.eiere | 12 |
Navn | Orgnr/født år | Aksjeklasse | Ant aksjer | Andel |
---|---|---|---|---|
Siva - Selskapet For Industrivekst Sf | 966703032 | Ordinære aksjer | 5,580 | 33.4% |
Universitetet I Tromsø - Norges Arktiske Universitet | 970422528 | Ordinære aksjer | 5,580 | 33.4% |
Equinor Energy AS | 990888213 | Ordinære aksjer | 1,575 | 9.4% |
Nordland Fylkeskommune | 964982953 | Ordinære aksjer | 752 | 4.5% |
Troms Og Finnmark Fylkeskommune Under Sletting Fra 01.01.2024 | 922420866 | Ordinære aksjer | 752 | 4.5% |
Sparebank 1 Nord-Norge Portefølje AS | 935491533 | Ordinære aksjer | 613 | 3.7% |
Troms Kraft AS | 979468792 | Ordinære aksjer | 578 | 3.5% |
Gjensidige Forsikring ASA | 995568217 | Ordinære aksjer | 578 | 3.5% |
Universitetssykehuset Nord-Norge Hf | 983974899 | Ordinære aksjer | 364 | 2.2% |
Hurtigruten Global Sales AS | 914904633 | Ordinære aksjer | 128 | 0.8% |
Helse Nord Rhf | 883658752 | Ordinære aksjer | 125 | 0.7% |
Fondet For Universitetet I Tromsø- Norges Arktiske Universitet | 977148146 | Ordinære aksjer | 86 | 0.5% |
Navn | Ant aksjer | Andel | Omsetning* | Driftsresultat* | Egenkapital* | Ant.eiere |
---|---|---|---|---|---|---|
Globesar AS | 258,730 | 100.0% | 0 | -6 | 806 | 1 |
Norinnova Startcap AS | 30,000 | 100.0% | 0 | -507 | -528 | 1 |
Forskningsparken Møtesenter AS | 13,750 | 100.0% | 8,908 | -65 | 2,284 | 1 |
Aranica AS | 1,600 | 74.4% | 2 | |||
Callmesmart AS | 50,000 | 50.0% | 0 | 0 | -411 | 2 |
Kinsea Lead Discovery AS | 7,556 | 25.2% | 408 | -969 | 1,871 | 8 |
Norinnova Invest AS | 8,217 | 18.4% | 0 | -60 | -12,398 | 28 |
Uformia AS | 29,672 | 13.0% | -3 | -93 | 10 | |
Orinor AS | 4,799 | 12.1% | 1,682 | 30 | 1,374 | 69 |
Avju Solutions AS | 2,486 | 9.3% | 13 | -563 | 324 | 15 |
Medsensio AS | 3,300 | 8.4% | 215 | -4 | 11 | 14 |
Prophylix Pharma Holding AS | 33,334 | 5.5% | -3 | 1,072 | 40 | |
Ctd AS | 1,500 | 4.2% | 128 | 1 | 141 | 6 |
Calanus AS | 797,020 | 3.8% | 2,123 | -1,502 | 5,704 | 60 |
Filmgrail AS | 7,000 | 3.0% | 89 | -366 | -352 | 21 |
Vitux Group AS | 1,109,078 | 2.8% | 454 | 82 | 6,090 | 36 |
Chip Nanoimaging AS | 1,875 | 2.8% | -69 | 467 | 5 | |
Prophylix Pharma Holding AS | 11,742 | 1.9% | -1 | 378 | 40 | |
Norinnova Invest AS | 829 | 1.9% | 0 | -6 | -1,251 | 28 |
Edinsights AS | 1,250 | 1.8% | 62 | 24 | 69 | 12 |
Probotic AS | 1,081 | 1.5% | 54 | -37 | 166 | 8 |
Prophylix Pharma Holding AS | 9,184 | 1.5% | -1 | 295 | 40 | |
Lyfstone AS | 139,730 | 0.9% | 9 | -3 | -8 | 116 |
Lytix Biopharma AS | 155,790 | 0.4% | 16 | -376 | 200 | 1,097 |
Amicoat AS | 88,186 | 0.3% | 51 | -13 | 162 | 311 |
Pharmasum Therapeutics AS | 8,307 | 0.3% | 4 | -4 | 7 | 683 |
Pharma Holdings AS | 1,760 | 0.2% | 3 | -26 | 28 | 291 |
* Justert for eierandel
Navn | Ant aksjer | Andel | Omsetning* | Driftsresultat* | Egenkapital* | Ant.eiere |
---|---|---|---|---|---|---|
Kirkeneskonferansen AS
Via Orinor AS |
36 | 12.1% | 134 | -45 | -51 | 1 |
Prophylix AS | 0 | 5.5% | -17 | -700 | 1 | |
3Dverket AS
Via Uformia AS |
929 | 4.6% | -0 | -0 | 2 | |
Zooca Calanus AS
Via Calanus AS |
1,140 | 3.8% | -0 | 1 | 1 | |
Salgard AS
Via Calanus AS |
260 | 3.8% | 10 | 6 | 20 | 1 |
Finnmarkskonferansen AS
Via Orinor AS |
13 | 2.9% | 45 | -2 | 2 | 3 |
Vitux Pharma AS
Via Vitux Group AS |
689 | 2.8% | -2 | 44 | 1 | |
Vitux AS
Via Vitux Group AS |
42 | 2.8% | 7,352 | 548 | 3,773 | 1 |
Nordkappregionen Næringshage AS
Via Orinor AS |
10 | 2.4% | 228 | 16 | 86 | 23 |
Prophylix Pharma Holding AS | 12,127 | 2.0% | -1 | 390 | 40 | |
Prophylix AS | 0 | 1.9% | -6 | -247 | 1 | |
Edinsights AS
Via Globesar AS |
1,250 | 1.8% | 62 | 24 | 69 | 12 |
Calanus AS | 352,422 | 1.7% | 939 | -664 | 2,522 | 60 |
Prophylix Pharma Holding AS | 10,193 | 1.7% | -1 | 328 | 40 | |
Vitux Group AS | 628,768 | 1.6% | 258 | 46 | 3,452 | 36 |
Prophylix AS | 0 | 1.5% | -5 | -193 | 1 | |
Tivoli North AS
Via Orinor AS |
12 | 1.3% | 6 | 0 | -1 | 5 |
Prophylix Pharma Holding AS | 6,514 | 1.1% | -1 | 210 | 40 | |
Prophylix Pharma Holding AS | 6,417 | 1.1% | -1 | 206 | 40 | |
Lyfstone AS | 85,996 | 0.5% | 5 | -2 | -5 | 116 |
Mk Evol AS
Via Orinor AS |
36 | 0.4% | 0 | -4 | 10 | 12 |
Lytix Biopharma AS | 102,599 | 0.3% | 10 | -248 | 131 | 1,097 |
Prophylix Pharma Holding AS | 1,223 | 0.2% | -0 | 39 | 40 | |
Calanus AS | 35,555 | 0.2% | 95 | -67 | 255 | 60 |
Prophylix Pharma Holding AS | 1,028 | 0.2% | -0 | 33 | 40 | |
Vitux Group AS | 63,435 | 0.2% | 26 | 5 | 348 | 36 |
Amicoat AS | 48,589 | 0.2% | 28 | -7 | 89 | 311 |
Peptide Patents AS
Via Amicoat AS |
0 | 0.1% | 2 | -0 | 1 | 2 |
Pharmasum Therapeutics AS | 4,299 | 0.1% | 2 | -2 | 4 | 683 |
Lyfstone Invest AS | 3,681 | 0.1% | 0 | -0 | 18 | 29 |
Prophylix Pharma Holding AS | 657 | 0.1% | -0 | 21 | 40 | |
Prophylix Pharma Holding AS | 647 | 0.1% | -0 | 21 | 40 | |
Uformia AS
Via Uformia AS |
232 | 0.1% | -0 | -1 | 10 | |
Pharma Holdings AS | 911 | 0.1% | 2 | -14 | 15 | 291 |
Peptide Patents AS | 0 | 0.1% | 1 | -0 | 1 | 2 |
Avju Solutions AS
Via Orinor AS |
22 | 0.1% | 0 | -5 | 3 | 15 |
Orinor AS
Via Orinor AS |
24 | 0.1% | 9 | 0 | 7 | 69 |
Lyfstone AS | 8,676 | 0.1% | 1 | -0 | -0 | 116 |
Lytix Biopharma AS | 10,351 | 0.0% | 1 | -25 | 13 | 1,097 |
Amicoat AS | 4,902 | 0.0% | 3 | -1 | 9 | 311 |
Pharmasum Therapeutics AS | 434 | 0.0% | 0 | -0 | 0 | 683 |
Lyfstone Invest AS | 371 | 0.0% | 0 | -0 | 2 | 29 |
Lyfstone AS
Via Lyfstone AS |
1,647 | 0.0% | 0 | -0 | -0 | 116 |
Lyfstone Invest AS
Via Lyfstone AS |
262 | 0.0% | 0 | -0 | 1 | 29 |
Pharma Holdings AS | 92 | 0.0% | 0 | -1 | 1 | 291 |
Pharmasum Therapeutics AS | 119 | 0.0% | 0 | -0 | 0 | 683 |
* Justert for eierandel